The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prescription Opioid Related Misuse, Harms, Diversion and Interventions in Canada: A Review
Open accessAbstract
Background: The non-medical use of and harms related to prescription opioid (PO) analgesics – key medications to treat severe and chronic pain - are an emerging public health concern globally. PO use is proportionally highest in North America, where, consequently, nonmedical PO use (NMPOU) and morbidity/mortality are high and well documented for the United States. Canada is the country with the second highest PO consumption rate in the world – with steeper recent increases in PO use than the US - mainly driven by substantial increases in the use of strong opioids (e.g., oxycodone). Indications and select data of NMPOU and PO-related morbidity and mortality have emerged in recent years, yet a systematic and comprehensive collection of relevant data to characterize the phenomenon in Canada does not exist. Objectives: This paper comprehensively reviews the available data in Canada regarding NMPOU, and PO-related harms, diversion, and interventions, and discusses implications for interventions and policy. Study Design: Narrative literature/data review. Setting: Canada. Methods: Publicly available data and information – either from journal publications, “grey literature” (e.g., government/technical reports) or Web sites reporting relevant data on Canada - were searched and narratively reviewed. Results: Indicators on NMPOU and PO-related harms in Canada are highly fragmented, and not nearly as systematic and comprehensive as they are in the US; virtually no national statistics/data are collected. Available –largely provincial/local - data indicate that PO misuse is increasingly common in key populations, including general adult and student populations, street-drug users, First Nations/Aboriginal Peoples, and correctional populations. Co-morbidities – e.g., pain, mental health problems, polysubstance use – among people reporting NMPOU appear to be high. Substance use treatment admissions for those with problematic PO use have risen substantially where reported. Opioid-related mortality (and oxycodone-related mortality, specifically) have increased considerably in Ontario where relevant data from the mid-1990s onward have been examined. In Canadian populations reporting NMPOU, sourcing of POs occurs through various diversion routes, including from family/friends, “double-doctoring,” or street drug markets. In addition, losses and theft/robberies from pharmacies and licensed medications dealers appear to be on the rise. Finally, interventions (i.e., provincial PO guidelines, prescription monitoring programs, substance use treatment services) are fragmented and inconsistently applied throughout the country, and currently fail to effectively address the growing problem of NMPOU and PO-related harms across Canada. Limitations: This review did not rely on systematic review methodologies. Conclusion: Corresponding to its increasing and high overall PO consumption levels, NMPOU and POrelated harms in Canada are high based on available data, and likely now constitute the third highest level of substance use burden of disease (after alcohol and tobacco). The data and monitoring situation in Canada regarding NMPOU and PO-related harms are fragmented, un-systematic, and insufficient. While major and concerted policy initiatives – primarily from the federal level - are absent to date, these urgently require vastly improved national data indicators and monitoring in order to allow for and evaluate evidence-based interventions on this urgent and extensive public health problem. Key words: Prescription opioids, pain, non-medical use, epidemiology, public health, morbidity, mortality, treatment, policy, Canada
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, R. D. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.121 · Cited by 540
Cited by
Guideline for opioid therapy and chronic noncancer pain
Busse, J. W., Craigie, S., Juurlink, D. N., Buckley, D. N., Wang, L., Couban, R. J., Agoritsas, T., Akl, E. A., Carrasco-Labra, A., Cooper, L., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170363 · Cited by 707
Inappropriate opioid prescription after surgery
Neuman, M. D., Bateman, B. T., & Wunsch, H. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30428-3 · Cited by 408
King, N. B., Fraser, V., Boikos, C., Richardson, R., & Harper, S. (2014) · American Journal of Public Health · doi:10.2105/ajph.2014.301966 · Cited by 310
Fairbairn, N., Coffin, P. O., & Walley, A. Y. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2017.06.005 · Cited by 274
Nielsen, S., Lintzeris, N., Bruno, R., Campbell, G., Larance, B., Hall, W., Hoban, B., Cohen, M. L., & Degenhardt, L. (2015) · Pain Medicine · doi:10.1111/pme.12594 · Cited by 131
Metadata
- Authors
- Fischer, B.
- Venue
- Pain Physician
- Published
- 2012-07-14
- Volume
- 3S;15
- Issue
- 3S;7
- Pages
- ES191-ES203
- ISSN
- 1533-3159 (ISSN-L)
- 2150-1149
- OpenAlex
- W2331081196
- Cited by
- 179
- References
- 1
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.